Skip to main content

Opportunities in Bispecific Therapy Development

October 17, 2023
Imperial Ballroom
The ability of bispecific antibodies and antibody drug conjugates to interact with two biologic binding sites at once creates major leverage for interfering with a disease mechanism intercellularly as well as heightened risks for predicting clinical results and for achieving manufacturing deadlines.  This session will examine the successes of the first generation of nearly a dozen approved immuno-oncology bispecifics and explore lessons from the more than 180 such programs in development worldwide, plus explore non-oncology opportunities for inflammatory diseases and more. 
Sofie Qiao, President and CEO - Virtuoso Therapeutics
Nancy Valente, Chief Medical Officer - Xencor
Sumant Ramachandra, CEO - ImmPACT Bio
Jun Bao, Chief Business Officer - Biotheus